The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Travelers Companies demonstrates consistent strength, with robust Q2 and Q3 2025 results, rebounding from Q1 losses and maintaining disciplined underwriting. TRV's strategic sale of its Canadian business and focus on U.S. operations enhance capital efficiency, with $700 million earmarked for additional share repurchases. Aggressive buybacks and consistent dividend growth highlight TRV's shareholder-friendly strategy, with $2 billion more in repurchases expected by Q1 2026.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Travelers (TRV) came out with quarterly earnings of $8.14 per share, beating the Zacks Consensus Estimate of $6.01 per share. This compares to earnings of $5.24 per share a year ago.
The insurance company beats earnings expectations for the sixth consecutive quarter.
TRV's Q3 results are likely to reflect solid top-line and investment income growth, aided by pricing discipline, retention strength and prudent underwriting.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Travelers (TRV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Travelers (TRV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Travelers' momentum in renewal rate improvements, high retention levels, and increased new business is likely to sustain its earnings growth.
The Travelers Companies, Inc. (NYSE:TRV ) Q2 2025 Earnings Conference Call July 17, 2025 9:30 AM ET Company Participants Abbe F. Goldstein - Senior Vice President of Investor Relations Alan David Schnitzer - Chairman & CEO Daniel Stephen Frey - Executive VP & CFO Gregory Cheshire Toczydlowski - Executive VP & President of Business Insurance Jeffrey Peter Klenk - Executive VP and President of Bond & Specialty Insurance Michael Frederick Klein - Executive VP & President of Personal Insurance Conference Call Participants Brian Robert Meredith - UBS Investment Bank, Research Division Cave Mohaghegh Montazeri - Deutsche Bank AG, Research Division Charles Gregory Peters - Raymond James & Associates, Inc., Research Division David Kenneth Motemaden - Evercore ISI Institutional Equities, Research Division Elyse Beth Greenspan - Wells Fargo Securities, LLC, Research Division Meyer Shields - Keefe, Bruyette, & Woods, Inc., Research Division Robert Cox - Goldman Sachs Group, Inc., Research Division Ryan Tunis - Unidentified Company Taylor Alexander Scott - Barclays Bank PLC, Research Division Vikram Gandhi - HSBC Global Investment Research Wesley Collin Carmichael - Autonomous Research US LP Operator Good morning, ladies and gentlemen.
TRV's Q2 results reflect growth in average invested assets, higher premiums, lower catastrophe losses and higher net favorable prior-year reserve development.